We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Vancomycin: We Can't Get There from Here.
- Authors
Patel, Nimish; Pai, Manjunath P.; Rodvold, Keith A.; Lomaestro, Ben; Drusano, George L.; Lodise, Thomas P.
- Abstract
Our findings indicate that vancomycin may not be useful for treating MRSA infections with MICs > 1 mg/L. Aggressive vancomycin dosing, producing an adequate drug exposure, is also associated with a high risk of nephrotoxicity, especially for ICU patients.(See the article by Kullar et al, on pages 975–981.)Background. We sought to characterize the pharmacodynamic profile of the more intensive vancomycin dosing regimens currently used in response to the recent vancomycin guidelines.Methods. A series of Monte Carlo simulations was performed for vancomycin regimens ranging from .5 g intravenous (IV) Q12H to 2 g IV Q12H. The probability of achieving an AUC/MIC ratio ≥ 400 for each dosing regimen was calculated for minimum inhibitory concentrations (MICs) from .5 to 2 mg/L. The risk of nephrotoxicity for each regimen was derived from a previously published vancomycin trough-nephrotoxicity logistic regression function. Restricted analyses were performed that only included subjects with troughs between 15 and 20 mg/L.Results. At a MIC of 2 mg/L, even the most aggressive dosing regimen considered (2 g every 12 h) only yielded a probability of target attainment (PTA) of 57% while generating a nephrotoxicity probability upward of 35%. At a MIC of 1 mg/L, ≥3 g per day provided PTA in excess of 80% but were associated with unacceptable risks of nephrotoxicity. In the restricted analyses of subjects with troughs between 15 and 20 mg/L, all regimens produced a PTA of 100% at MICs ≤1 mg/L. The PTA was variable among the regimens at a MIC of 2 mg/L and was highly dependent on the total daily dose administered.Conclusions. This study indicates that vancomycin may not be useful for treating serious methicillin-resistant Staphylococcus aureus (MRSA) infections with MIC values > 1 mg/L where PTA is questionable. Since an AUC/MIC ratio ≥ 400 is target associated with efficacy, one should consider incorporating computation of AUC when monitoring vancomycin.
- Subjects
VANCOMYCIN; METHICILLIN-resistant staphylococcus aureus; DOSAGE forms of drugs; NEPHROTOXICOLOGY; BIOLOGICAL monitoring; LOGISTIC regression analysis
- Publication
Clinical Infectious Diseases, 2011, Vol 52, Issue 8, p969
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/cir078